30+ Presentations from Top Pharma at Drug Discovery Chemistry 2023

As in the past, speaker participation by industry is once again very strong, with presentations from AbbVie, Amgen, Astex Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Genentech, GlaxoSmithKline, Janssen, Johnson & Johnson, Merck, Novartis, Pfizer, and more. Preview some of the 30+ presentations* below:

Identification of the in vivo active KRAS G12C Inhibitor BI-0474 via Fragment Based Screening and Optimization of Reversible Binding to KRAS

Joachim Broeker, PhD, Principal Scientist, Medicinal Chemistry, Boehringer Ingelheim RCV GmbH & Co. KG

Structural and Biophysical Studies of Protein Degrader Ternary Complexes

Matthew Calabrese, PhD, Senior Director & Head, Structural & Molecular Sciences, Pfizer Global R&D

Development and Characterization of NVP-DKY709, a Selective IKZF2/4 Glue Degrader that Inhibits Regulatory T Cell Activity

Artiom Cernijenko, PhD, Principal Scientist II, Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc.

Targeted Covalent Inhibitor Assay Strategies: ADME Perspective

Upendra Dahal, PhD, Senior Principal Scientist, Pharmacokinetics and Drug Metabolism, Amgen, Inc.

Chimeric BRM Degraders and Degrader-Antibody Conjugates

Peter S. Dragovich, PhD, Senior Fellow, Discovery Chemistry, Genentech, Inc.

High-Throughput Protein Analysis Enabled by IR-MALDESI-MS

Nathaniel L. Elsen, PhD, Principal Research Scientist, Discovery, AbbVie, Inc.

Utilizing the SPR Chaser Assay in a Medicinal Chemistry Assay Cascade

Thomas P. Garner, PhD, Senior Scientist, Biophysics, Genentech, Inc.

Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation

Charles Hendrick, PhD, Senior Scientist, Discovery Chemistry, Janssen R&D LLC

Inhibiting TEAD Using Fragment Approaches

Timo Heinrich, PhD, Associate Scientific Director, Oncology, EMD Serono

Evolving a Fragment-Like Molecule to Multiple Clinical Candidates: Novel Pan-Metallo-β-Lactamase Inhibitors (MBLi) for Potentiation of β-Lactam-Based Antibiotics

Mihir Mandal, PhD, Principal Scientist, Medicinal Chemistry, Merck

Drug Discovery Applications of Covalent Fragments in Neuroscience

Jeffrey Martin, PhD, Scientist II, Drug Discovery, Biogen

Selectively Inhibiting Kinase HPK1 for Immuno-Oncology

Ryan McClure, PhD, Senior Scientist, Drug Discovery Science & Technology, AbbVie

Oral Peptides: Theory and Practice

Lauren G. Monovich, PhD, Director, Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc.

Covalent Fragment Screening and Hit Characterization Methods for Efficient Covalent Drug Discovery

Mela Mulvihill, PhD, Director and Senior Principal Scientist, Biochemical & Cellular Pharmacology, Genentech, Inc.

Applying Machine Learning to DEL Hit Selection

Patrick Neal, PhD, Analyst, Chemoinformatics, GlaxoSmithKline

In silico Screening for PROTAC Linkers

Shu-Ching Ou, PhD, Scientist, Center for Research Acceleration by Digital Innovation, Amgen, Inc.

Accelerated Screening and Optimization of DEL-Hits: Cleavable Linker Platform (CLiP)

Anokha S. Ratnayake, PhD, Principal Scientist, Design and Synthesis Sciences, DNA Encoded Library Technology Group, Pfizer Global R&D Groton Laboratories

MedChem Case Study of HIV Maturation Inhibitor Candidates

Alicia Regueiro-Ren, PhD, Director, Medicinal Chemistry, Bristol Myers Squibb Co.

AI and Informatics Navigation of Huge Chemical Spaces

Mark Seierstad, PhD, Senior Principal Scientist, Computer Aided Drug Discovery, Johnson & Johnson Pharmaceutical R&D

Discover Protein Degraders for Cancer Therapy: Expect the Unexpected

Yu Shen, PhD, Director, Cancer Biology, AbbVie, Inc.

Machine Learning-based Identification of Targets in Cancer for Protein Degradation

Collin Tokheim, PhD, Senior Scientist, Early Oncology Data Science, AstraZeneca Pharmaceuticals

DEL Selections for Molecular Glues

Audrey E. Tolbert, PhD, Investigator, Encoded Library Technology Biology, GlaxoSmithKline

3D Pride without 2D Prejudice: Bias-Controlled Generative Models for Structure-Based Design

Marcel Verdonk, PhD, Senior Director, Computational Chemistry & Informatics, Astex Pharmaceuticals

Fragment Screening Combined with Corporate Compound Collection Searching: Delivering a Novel Inhibitor of the KEAP1:NRF2 Interaction

Marcel Verdonk, PhD, Senior Director, Computational Chemistry & Informatics, Astex Pharmaceuticals

In silico ADME: Application and Impact of QSAR Models in Drug Discovery

Wenyi Wang, PhD, Principal Scientist, DMPK Department, Genentech, Inc.

Structural and Mechanistic Understanding of Cereblon as a Target of Molecular Glues

Edmond Watson, PhD, Senior Scientist, Bristol Myers Squibb Co.

Discovery and Optimization of an Oral PCSK9 Macrocyclic Inhibitor from mRNA Display Screening

Chengwei Wu, Senior Scientist, Discovery Chemistry, Merck & Co., Inc.

Attacking Intrinsically Disordered Protein with Fragments

Haihong Wu, PhD, Senior Scientist II, Global Protein Sciences, AbbVie, Inc.

Enabling Technologies to Determine Absolute Protein Abundance and Degradation Kinetics for PROTACs

Hua Xu, PhD, Director, Mechanistic Biology & Profiling, AstraZeneca

Facilitating DEL Hit Triage: Estimating Data Noise Level via Selection Replicate Samples

Hongyao Zhu, PhD, Associate Research Fellow, Machine Learning and Computational Sciences, Pfizer Inc.

* As of 12/5/2022 – Please see individual agenda pages for most up-to-date list of speakers